SIC 2836 · Manufacturing
Biological Products, (No Diagnostic Substances)
OpenFilings tracks 61 companies that the SEC classifies under Standard Industrial Classification code 2836; the most recent filing among them is dated Oct 27, 2026. 59 of them report standardized annual figures in XBRL, shown in the revenue column.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. Not investment advice.
Companies in this industry
| # | Company | State | Latest filing | Revenue (latest FY) |
|---|---|---|---|---|
| 55 | AMGN AMGEN INC | CA | Oct 27, 2026 | $36.8BFY2025 |
| 71 | GILD GILEAD SCIENCES, INC. | CA | Oct 16, 2026 | $29.4BFY2025 |
| 235 | MRNA Moderna, Inc. | MA | Oct 16, 2026 | $1.9BFY2025 |
| 295 | ARGX ARGENX SE | — | Oct 22, 2026 | —FY2025 |
| 380 | RVMD Revolution Medicines, Inc. | CA | Oct 13, 2026 | $0FY2025 |
| 400 | BIIB BIOGEN INC. | MA | Oct 5, 2026 | $9.9BFY2025 |
| 555 | BNTX BioNTech SE | Germany | Oct 26, 2026 | EUR 2.9BFY2025 |
| 669 | EXEL EXELIXIS, INC. | CA | Sep 11, 2026 | $2.3BFY2026 |
| 720 | NBIX NEUROCRINE BIOSCIENCES INC | CA | Oct 15, 2026 | $2.9BFY2025 |
| 736 | HALO HALOZYME THERAPEUTICS, INC. | CA | Oct 8, 2026 | $1.4BFY2025 |
| 835 | TECH BIO-TECHNE Corp | MN | Sep 30, 2026 | $1.2BFY2026 |
| 846 | RGEN REPLIGEN CORP | MA | Oct 27, 2026 | $738.3MFY2025 |
| 889 | QGEN QIAGEN N.V. | — | Oct 23, 2026 | $2.1BFY2025 |
| 915 | PCVX Vaxcyte, Inc. | CA | Oct 9, 2026 | —FY2025 |
| 940 | KRYS Krystal Biotech, Inc. | PA | Oct 27, 2026 | $389.1MFY2025 |
| 957 | KYMR Kymera Therapeutics, Inc. | MA | Oct 27, 2026 | $39.2MFY2025 |
| 975 | TWST Twist Bioscience Corp | CA | Oct 27, 2026 | $376.6MFY2025 |
| 985 | IBRX ImmunityBio, Inc. | CA | Oct 14, 2026 | $113.3MFY2025 |
| 1159 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | CA | Oct 5, 2026 | $263.5MFY2025 |
| 1202 | IMVT Immunovant, Inc. | NC | Oct 23, 2026 | —FY2026 |
| 1265 | CGON CG Oncology, Inc. | TX | Oct 19, 2026 | $4.0MFY2025 |
| 1288 | KOD Kodiak Sciences Inc. | CA | Oct 26, 2026 | —FY2025 |
| 1322 | SRRK Scholar Rock Holding Corp | MA | Oct 27, 2026 | $0FY2025 |
| 1362 | CRSP CRISPR Therapeutics AG | — | Oct 21, 2026 | $3.5MFY2025 |
| 1504 | RLAY Relay Therapeutics, Inc. | MA | Oct 8, 2026 | $15.4MFY2025 |
| 1529 | ADPT Adaptive Biotechnologies Corp | WA | Oct 26, 2026 | $277.0MFY2025 |
| 1625 | TARS Tarsus Pharmaceuticals, Inc. | CA | Oct 13, 2026 | $451.4MFY2025 |
| 1705 | DNLI Denali Therapeutics Inc. | CA | Sep 9, 2026 | $0FY2025 |
| 1824 | BEAM Beam Therapeutics Inc. | MA | Oct 16, 2026 | $139.7MFY2025 |
| 1837 | ADMA ADMA BIOLOGICS, INC. | NJ | Aug 7, 2026 | $510.2MFY2025 |
| 1909 | VCEL Vericel Corp | MA | Aug 14, 2026 | $276.3MFY2025 |
| 1990 | BCRX BIOCRYST PHARMACEUTICALS INC | NC | Sep 2, 2026 | $874.8MFY2025 |
| 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | UT | Oct 15, 2026 | $74.7MFY2025 |
| 2061 | MAZE Maze Therapeutics, Inc. | CA | Oct 16, 2026 | —FY2025 |
| 2070 | VIR Vir Biotechnology, Inc. | CA | Oct 27, 2026 | $68.6MFY2025 |
| 2084 | ALVO Alvotech | Luxembourg | Oct 20, 2026 | $586.3MFY2025 |
| 2114 | IMCR Immunocore Holdings plc | United Kingdom | Oct 7, 2026 | $400.0MFY2025 |
| 2126 | MESO MESOBLAST LTD | Australia | Oct 16, 2026 | $17.2MFY2025 |
| 2132 | NVAX NOVAVAX INC | MD | Oct 16, 2026 | $1.1BFY2025 |
| 2218 | INBX Inhibrx Biosciences, Inc. | CA | Oct 14, 2026 | $1.3MFY2025 |
| 2261 | TSHA Taysha Gene Therapies, Inc. | TX | Aug 14, 2026 | $9.8MFY2025 |
| 2343 | IMTX Immatics N.V. | Germany | Oct 26, 2026 | —FY2025 |
| 2357 | REPL Replimune Group, Inc. | MA | Sep 16, 2026 | —FY2026 |
| 2364 | VOR Vor Biopharma Inc. | MA | Oct 5, 2026 | —FY2025 |
| 2466 | GLUE Monte Rosa Therapeutics, Inc. | MA | Oct 6, 2026 | $123.7MFY2025 |
| 2472 | MGTX MeiraGTx Holdings plc | NY | Oct 20, 2026 | $81.4MFY2025 |
| 2487 | CGEM Cullinan Therapeutics, Inc. | MA | Oct 2, 2026 | —FY2025 |
| 2603 | SLBT SL Science Holding Ltd | — | Oct 26, 2026 | — |
| 2663 | SANA Sana Biotechnology, Inc. | WA | Oct 6, 2026 | —FY2025 |
| 2710 | FDMT 4D Molecular Therapeutics, Inc. | CA | Oct 20, 2026 | $85.2MFY2025 |
| 2716 | AURA Aura Biosciences, Inc. | MA | Oct 27, 2026 | —FY2025 |
| 2719 | PRME Prime Medicine, Inc. | MA | Aug 6, 2026 | $4.6MFY2025 |
| 2727 | SLDB Solid Biosciences Inc. | MA | Oct 26, 2026 | —FY2025 |
| 2736 | DNA Ginkgo Bioworks Holdings, Inc. | MA | Oct 21, 2026 | $170.2MFY2025 |
| 2751 | CADL Candel Therapeutics, Inc. | MA | Oct 2, 2026 | —FY2025 |
| 2782 | DBVT DBV Technologies S.A. | — | Sep 30, 2026 | $5.6MFY2025 |
| 2824 | PROK PROKIDNEY CORP. | NC | Aug 20, 2026 | $893.0KFY2025 |
| 2879 | ENTX Entera Bio Ltd. | — | Oct 27, 2026 | $42.0KFY2025 |
| 2899 | VALN Valneva SE | France | Oct 15, 2026 | EUR 174.7MFY2025 |
| 2944 | RGNX REGENXBIO Inc. | MD | Oct 16, 2026 | $170.4MFY2025 |
| 2979 | AGMB AgomAb Therapeutics NV | — | Oct 22, 2026 | — |
Ranked by position in the SEC company ticker list (roughly by market value) among all companies we track. Revenue is the latest full fiscal year; amounts in a foreign currency are shown with its code.
Advertisement
Latest reports from these companies
Annual, quarterly and current reports and proxy statements filed by the companies above, newest first.
| Filed | Company | Form | What it is | Original |
|---|---|---|---|---|
| Oct 27, 2026 | AMGN AMGEN INC | 8-K | Director or officer change· period Oct 26, 2026 | Document · Index |
| Oct 27, 2026 | ENTX Entera Bio Ltd. | 8-K | Director or officer change; Regulation FD disclosure· period Oct 27, 2026 | Document · Index |
| Oct 27, 2026 | RGEN REPLIGEN CORP | 8-K | Results of operations· period Oct 27, 2026 | Document · Index |
| Oct 26, 2026 | BNTX BioNTech SE | 6-K | Report of a foreign private issuer· period Oct 26, 2026 | Document · Index |
| Oct 26, 2026 | BNTX BioNTech SE | 6-K | Report of a foreign private issuer· period Oct 26, 2026 | Document · Index |
| Oct 26, 2026 | IMTX Immatics N.V. | 6-K | Report of a foreign private issuer· period Oct 24, 2026 | Document · Index |
| Oct 26, 2026 | SLBT SL Science Holding Ltd | 6-K | Report of a foreign private issuer· period Jun 30, 2026 | Document · Index |
| Oct 23, 2026 | IMTX Immatics N.V. | 6-K | Report of a foreign private issuer· period Oct 23, 2026 | Document · Index |
| Oct 23, 2026 | QGEN QIAGEN N.V. | 6-K | FORM 6K· period Oct 23, 2026 | Document · Index |
| Oct 22, 2026 | ARGX ARGENX SE | 6-K | Report of a foreign private issuer· period Sep 30, 2026 | Document · Index |
| Oct 22, 2026 | BNTX BioNTech SE | 6-K | Report of a foreign private issuer· period Oct 22, 2026 | Document · Index |
| Oct 20, 2026 | ALVO Alvotech | 6-K | Report of a foreign private issuer· period Oct 20, 2026 | Document · Index |
| Oct 19, 2026 | ARGX ARGENX SE | 6-K | Report of a foreign private issuer· period Oct 19, 2026 | Document · Index |
| Oct 19, 2026 | BNTX BioNTech SE | 6-K | Report of a foreign private issuer· period Oct 19, 2026 | Document · Index |
| Oct 19, 2026 | CRSP CRISPR Therapeutics AG | 8-K | Director or officer change· period Oct 19, 2026 | Document · Index |
| Oct 16, 2026 | MAZE Maze Therapeutics, Inc. | 8-K | Material agreement; Unregistered equity sale· period Oct 15, 2026 | Document · Index |
| Oct 16, 2026 | MESO MESOBLAST LTD | 6-K | Report of a foreign private issuer· period Oct 16, 2026 | Document · Index |
| Oct 16, 2026 | RGNX REGENXBIO Inc. | 8-K | Director or officer change· period Oct 14, 2026 | Document · Index |
| Oct 15, 2026 | KRYS Krystal Biotech, Inc. | 8-K | Regulation FD disclosure· period Oct 15, 2026 | Document · Index |
| Oct 15, 2026 | MESO MESOBLAST LTD | 6-K | Report of a foreign private issuer· period Oct 14, 2026 | Document · Index |
| Oct 15, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | 8-K | Material agreement; Results of operations; Regulation FD disclosure; Other events· period Oct 15, 2026 | Document · Index |
| Oct 15, 2026 | VALN Valneva SE | 6-K | Report of a foreign private issuer· period Dec 31, 2026 | Document · Index |
| Oct 14, 2026 | ALVO Alvotech | 6-K | Report of a foreign private issuer· period Oct 14, 2026 | Document · Index |
| Oct 14, 2026 | ENTX Entera Bio Ltd. | DEF 14A | Definitive proxy statement· period Oct 14, 2026 | Document · Index |
| Oct 14, 2026 | IBRX ImmunityBio, Inc. | 8-K | Regulation FD disclosure· period Oct 14, 2026 | Document · Index |
Related industries in Manufacturing
- Pharmaceutical Preparations (194)
- Semiconductors & Related Devices (71)
- Surgical & Medical Instruments & Apparatus (51)
- Motor Vehicle Parts & Accessories (21)
- Motor Vehicles & Passenger Car Bodies (17)
- Petroleum Refining (17)
- Miscellaneous Electrical Machinery, Equipment & Supplies (15)
- Radio & Tv Broadcasting & Communications Equipment (13)
- Laboratory Analytical Instruments (12)
- Beverages (11)
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (11)
- Steel Works, Blast Furnaces & Rolling Mills (Coke Ovens) (11)
Source
- U.S. Securities and Exchange Commission, EDGAR company submissions (SIC code and description) and XBRL company facts. The SEC does not endorse OpenFilings.
Advertisement